Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from PhRMA

10:49 EDT 23rd September 2018 | BioPortfolio

Here are the most relevant search results for "PhRMA" found in our extensive news archives from over 250 global news sources.

More Information about PhRMA on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PhRMA for you to read. Along with our medical data and news we also list PhRMA Clinical Trials, which are updated daily. BioPortfolio also has a large database of PhRMA Companies for you to search.

Showing News Articles 1–25 of 226 from PhRMA

Thursday 20th September 2018

At this year’s UN High-Level Meeting, nations will decide how to combat the tuberculosis public health crisis. TB presents unique challenges, and it’s essential to know the difference between fact and fiction when discussing solutions. https://onphr.

At this year’s UN High-Level Meeting, nations will decide how to combat the tuberculosis public health crisis. TB presents unique challenges, and it’s essential to know the difference between fact and fiction when discussing solutions. https://onphr.ma/2NXLwBT  #endTB #UNHLM

Five myths about global efforts to combat tuberculosis

On September 26, world leaders will convene in New York for the first-ever United Nations (UN) High-Level Meeting on Ending Tuberculosis (TB). This event could not be more critical – or more timely –  because even though TB kills more than one million people per year, it has not received enough attention from global policymakers.

Wednesday 19th September 2018

Jake Marazzo was diagnosed with Duchenne muscular dystrophy as a child. Today, he uses his experience with the disease to inspire others in his situation to live every day to the fullest. #GoBoldly http://bit.ly/2OC1Zc5 pic.twitter.com/fvl4Fa7pL6

Jake Marazzo was diagnosed with Duchenne muscular dystrophy as a child. Today, he uses his experience with the disease to inspire others in his situation to live every day to the fullest. #GoBoldly http://bit.ly/2OC1Zc5  pic.twitter.com/fvl4Fa7pL6

New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers

A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be very useful for private payers’ medicine coverage decisions. The whitepaper identifies several problems in applying ICER’s reports to inform coverage

Tuesday 18th September 2018

Great conversation underway at @MAPRx event. You can watch live at https://maprx.info/ . Up next, a panel conversation with policy experts @jwhite_health @JNJNews and Dean Rosen. #StrengthenPartDpic.twitter.com/TJmHbndaV3

Great conversation underway at @MAPRx event. You can watch live at https://maprx.info/ . Up next, a panel conversation with policy experts @jwhite_health @JNJNews and Dean Rosen. #StrengthenPartD pic.twitter.com/TJmHbndaV3

Terrific new report on Medicare #PartD released today by @MAPRx. Touts the successes of this critical program, highlights the existing challenges for beneficiaries, and offers solutions to #StrengthenPartD. Read here: http://maprx.info/15YearReport 

Terrific new report on Medicare #PartD released today by @MAPRx. Touts the successes of this critical program, highlights the existing challenges for beneficiaries, and offers solutions to #StrengthenPartD. Read here: http://maprx.info/15YearReport 

If Congress does not act, some Medicare Part D patients could face an extra $1,250 in OOP drug costs starting in 2020. #StrengthenPartDpic.twitter.com/AmOVZMyosl

If Congress does not act, some Medicare Part D patients could face an extra $1,250 in OOP drug costs starting in 2020. #StrengthenPartD pic.twitter.com/AmOVZMyosl

Patient advocates sharing stories about the launch of Part D and where we are today. @AIDSInstitute @NCOAging @ACSCAN @NAMIAdvocacy #StrengthenPartDpic.twitter.com/EMeREBxvyk

Patient advocates sharing stories about the launch of Part D and where we are today. @AIDSInstitute @NCOAging @ACSCAN @NAMIAdvocacy #StrengthenPartD pic.twitter.com/EMeREBxvyk

Up now at @MAPRx “Fifteen Years of Part D” Session 1 - a panel discussion with patient advocates. @AIDSadvocacy @NCOAging @NAMICommunicate @ACSCAN #StrengthenPartDpic.twitter.com/qwms56BK8O

Up now at @MAPRx “Fifteen Years of Part D” Session 1 - a panel discussion with patient advocates. @AIDSadvocacy @NCOAging @NAMICommunicate @ACSCAN #StrengthenPartD

Excited for this rockstar patient advocate panel! #StrengthenPartD @MAPRxpic.twitter.com/oiCTv1NwUe

Excited for this rockstar patient advocate panel! #StrengthenPartD @MAPRx pic.twitter.com/oiCTv1NwUe

Medicare Part D aims to lower costs and provide access to lifesaving medications through a competitive insurance marketplace #StrengthenPartD

Medicare Part D aims to lower costs and provide access to lifesaving medications through a competitive insurance marketplace #StrengthenPartD

.@LupusOrg CEO Sandra Raymond: A key hallmark of the Part D success story has been that the actual cost of the program have beat the projections when the program was started. #StrengthenPartD @MAPRxpic.twitter.com/iEsGHjsWEa

. @LupusOrg CEO Sandra Raymond: A key hallmark of the Part D success story has been that the actual cost of the program have beat the projections when the program was started. #StrengthenPartD @MAPRx pic.twitter.com/iEsGHjsWEa

We are excited to welcome our @MAPRx members, guests, and panelists as we celebrate 15 years of success with Medicare #PartD! #StrengthenPartDpic.twitter.com/CAMq97Dnm2

We are excited to welcome our @MAPRx members, guests, and panelists as we celebrate 15 years of success with Medicare #PartD! #StrengthenPartD pic.twitter.com/CAMq97Dnm2

Watch @MAPRx throughout today as part of the celebration of 15 years of Medicare Part D and the life-saving access to prescription drugs it has provided for seniors all around the country. #StrengthenPartDpic.twitter.com/ma4WzDkFqF

Watch @MAPRx throughout today as part of the celebration of 15 years of Medicare Part D and the life-saving access to prescription drugs it has provided for seniors all around the country. #StrengthenPartD pic.twitter.com/ma4WzDkFqF

Monday 17th September 2018

Any minute, a powerful story will be told @thehamiltondc during a screening of “The Turning Point.” Thanks to @AtlanticLIVE for partnering with us to tell this story of innovation & a commitment to patients in the search for an Alzheimer's cure. #GoBo

Any minute, a powerful story will be told @thehamiltondc during a screening of “The Turning Point.” Thanks to @AtlanticLIVE for partnering with us to tell this story of innovation & a commitment to patients in the search for an Alzheimer's cure. #GoBoldly http://bit.ly/2pd6ZIZ 

Did you know that dogs & children spontaneously develop a number of similar cancers. Read 'Saving kids and dogs from shared cancers' by guest contributor Ulrike Szalay, founder of the @CNKFoundation. Learn about their upcoming race. https://catalyst.phrm

Did you know that dogs & children spontaneously develop a number of similar cancers. Read 'Saving kids and dogs from shared cancers' by guest contributor Ulrike Szalay, founder of the @CNKFoundation. Learn about their upcoming race. https://catalyst.phrma.org/saving-kids-and-dogs-from-shared-cancers … #EndChildhoodCancer

Saving kids and dogs from shared cancers

Ulrike Szalay is the Founder and Executive Director of Canines-N-Kids Foundation Did you know? Dogs and children spontaneously develop a number of similar cancers. In fact, cancer is the leading cause of disease-related childhood mortality in the U.S. and affects

The biopharmaceutical industry is committed to tackling #Alzheimer’s. Tonight, we’re sharing one story of setbacks, perseverance and our commitment to patients to #EndAlz in a screening of "The Turning Point" in Washington, DC. To attend, RSVP here:

The biopharmaceutical industry is committed to tackling #Alzheimer’s. Tonight, we’re sharing one story of setbacks, perseverance and our commitment to patients to #EndAlz in a screening of "The Turning Point" in Washington, DC. To attend, RSVP here: http://bit.ly/2QBQm6c  pic.twitter.com/dcv4v2Ssof

Friday 14th September 2018

Dr. Jane Owens of @pfizer's Rare Disease Research Unit uses gene therapy to help design more effective treatments for Duchenne muscular dystrophy. Learn more about Jane's work at http://bit.ly/2OqOewQ  #GoBoldlypic.twitter.com/mjohjqvMZ3

Dr. Jane Owens of @pfizer's Rare Disease Research Unit uses gene therapy to help design more effective treatments for Duchenne muscular dystrophy. Learn more about Jane's work at http://bit.ly/2OqOewQ  #GoBoldly pic.twitter.com/mjohjqvMZ3

Thursday 13th September 2018

Pharma alternative payment models: Can the Industry Learn To Play Well With Others? http://bit.ly/2Oh4kZO  @millimanhealth

Pharma alternative payment models: Can the Industry Learn To Play Well With Others? http://bit.ly/2Oh4kZO  @millimanhealth

Patient advocate and @GSKUS spokesperson Jamie Schanbaum won her battle with meningitis. Now, she's sharing her story to help protect others against the deadly disease. #GoBoldly http://bit.ly/2p3Uob1 pic.twitter.com/tezs2CMdCO

Patient advocate and @GSKUS spokesperson Jamie Schanbaum won her battle with meningitis. Now, she's sharing her story to help protect others against the deadly disease. #GoBoldly http://bit.ly/2p3Uob1  pic.twitter.com/tezs2CMdCO

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines.  These fixes would leave seniors with high drug spending better off while stabilizing the program for the long-term.

Wednesday 12th September 2018

Despite setbacks in #Alzheimer's research, a new report highlights the tremendous promise of the pipeline to deliver new treatments to patients. Read the report here: https://onphr.ma/2Mqevt8 pic.twitter.com/aFzGYZv3hb

Despite setbacks in #Alzheimer's research, a new report highlights the tremendous promise of the pipeline to deliver new treatments to patients. Read the report here: https://onphr.ma/2Mqevt8  pic.twitter.com/aFzGYZv3hb

Recent comments from the CEO of generic manufacturer Nostrum Laboratories are tone deaf, particularly as patients are increasingly facing affordability challenges in the marketplace.

Recent comments from the CEO of generic manufacturer Nostrum Laboratories are tone deaf, particularly as patients are increasingly facing affordability challenges in the marketplace.

Today’s discussion at #AtlanticStateofCare is just the beginning. Read the new Setbacks and Stepping Stones report out now for more on the future of #Alzheimers research: https://onphr.ma/2x2IwKI pic.twitter.com/uNb5dbuXdc

Today’s discussion at #AtlanticStateofCare is just the beginning. Read the new Setbacks and Stepping Stones report out now for more on the future of #Alzheimers research: https://onphr.ma/2x2IwKI  pic.twitter.com/uNb5dbuXdc


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks